Viral Vector and Plasmid DNA Manufacturing Market Share 2031

Segments - Viral Vector and Plasmid DNA Manufacturing Market by Applications (Genetic Disorders, Infectious Diseases, Cancers, and Others), Product Types (Viral Vector, Non-viral Vector, and Plasmid DNA), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028.

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

The global viral vector and plasmid DNA manufacturing market size was valued at USD 591 million in 2020 and is projected to expand at a robust CAGR during the forecast period, 2021–2028. The growth of the market is attributed to increasing demand for viral vector-based vaccinations for contagious diseases

Viral vectors are widely utilized by molecular techniques to transport genetic elements into cells. Viruses evolve specific molecular pathways for efficient transport of their DNA inside cells infected by them only through the transduction process.

Viral vectors and plasmid DNA are used in gene therapy to treat a variety of diseases such as heart abnormalities, metabolic problems, cancers, and neurological disorders. Viral vectors based on adenoviruses and herpes simplex viruses are finding more usage in vaccine production and innovative medication discovery.

Market Trends, Drivers, Restraints and Opportunities

Increasing prevalence of cancer is anticipated to drive the market growth.
Rising number of gene therapy applicants, which are progressing rapidly through stage of clinical development, is estimated to drive viral vector and plasmid DNA industrial production.
Growing funding for gene therapy research and development activities as well as increasing public awareness about gene therapy are fueling the market growth.
The risk of mutation as well as the high cost of genetic testing and other impediments to gene therapy can hamper the market growth.
The global market for synthetic genes and the unexplored developing market potential are estimated to generate opportunity for market participants during the projection period.
The COVID-19 pandemic has provided significant opportunities for market participants and has increased demand for viral vectors, resulting in increased revenues for viral vector manufacturers.

Scope of the Report

The report on the global viral vector and plasmid DNA manufacturing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2020
Historic Data	2018–2019
Forecast Period	2021–2028
Segmentation	Applications (Genetic Disorders, Infectious Diseases, Cancers, and Others), and Product Types (Viral Vector, Non-viral Vector, and Plasmid DNA)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Thermo Fisher Scientific; SIRION Biotech; Fujifilm Diosynth Biotechnologies; Merck KGaA Inc.; Cognate BioServices Inc. (Cobra Biologics); and Others

Viral Vector and Plasmid DNA Manufacturing Market Segment Insights

Genetic disorder segment is expected to grow at a rapid pace

Based on applications, the market is divided into genetic disorders, infectious diseases, cancers, and others. The genetic disorders segment is expected to grow at a rapid pace during the forecast period. Growing engagement of the scientific community in gene and cell therapy research activities is projected to propel the global demand for viral vectors. However, the cancer segment is anticipated to dominate the industry. This segment contributed for more than for 35% revenue in 2020. Viruses have shown to be an effective vector for the generation of gene therapy against a variety of different cancers.

Viral vector segment is projected to expand at a considerable CAGR

On the basis of product types, the viral vector and plasmid DNA manufacturing market is segregated viral vector, non-viral vector, and plasmid DNA. The viral vector segment is anticipated to account for a major market share during the forecast period. Increasing use of viral vectors in vaccine production owing to their operational efficiencies and advantages such as ability to generate a wide immunological response, safety profiles, and ease of manufacture.

Middle East & Africa anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of the Middle East & Africa is expected to constitute a key share of the market during the projected period. Novel viral vectors are rapidly evolving, and numerous researchers are working on replacing harmful genes with therapeutic genes. However, North America is anticipated to expand at a rapid pace during the forecast period The North American viral vector and plasmid DNA production industry is currently experiencing significant expansion owing to rapid innovation in the development of viral vector product methods.

Segments

Segments Covered in the Report

The global viral vector and plasmid DNA manufacturing market has been segmented on the basis of

Applications

Genetic Disorders
Infectious Diseases
Cancers
Others

Product types

Viral Vector
Non-viral Vector
Plasmid DNA

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Thermo Fisher Scientific
SIRION Biotech
Fujifilm Diosynth Biotechnologies
Merck KGaA Inc.
Cognate BioServices Inc. (Cobra Biologics)

Competitive Landscape

The market is very competitive in nature owing to the presence of many major players. Some of the major players competing in the global viral vector and plasmid DNA manufacturing market are Thermo Fisher Scientific; SIRION Biotech; Fujifilm Diosynth Biotechnologies; Merck KGaA Inc.; Cognate BioServices Inc. (Cobra Biologics), and Others

Viral Vector and Plasmid DNA Manufacturing Market

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Viral Vector and Plasmid DNA Manufacturing Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Viral Vector and Plasmid DNA Manufacturing Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Viral Vector and Plasmid DNA Manufacturing Market - Supply Chain
  4.5. Global Viral Vector and Plasmid DNA Manufacturing Market Forecast
     4.5.1. Viral Vector and Plasmid DNA Manufacturing Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Viral Vector and Plasmid DNA Manufacturing Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Viral Vector and Plasmid DNA Manufacturing Market Absolute $ Opportunity
5. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Viral Vector and Plasmid DNA Manufacturing Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Viral Vector and Plasmid DNA Manufacturing Demand Share Forecast, 2019-2026
6. North America Viral Vector and Plasmid DNA Manufacturing Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Viral Vector and Plasmid DNA Manufacturing Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Viral Vector and Plasmid DNA Manufacturing Demand Share Forecast, 2019-2026
7. Latin America Viral Vector and Plasmid DNA Manufacturing Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Viral Vector and Plasmid DNA Manufacturing Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Viral Vector and Plasmid DNA Manufacturing Demand Share Forecast, 2019-2026
8. Europe Viral Vector and Plasmid DNA Manufacturing Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Viral Vector and Plasmid DNA Manufacturing Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Viral Vector and Plasmid DNA Manufacturing Demand Share Forecast, 2019-2026
9. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Demand Share Forecast, 2019-2026
10. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Viral Vector and Plasmid DNA Manufacturing Market: Market Share Analysis
  11.2. Viral Vector and Plasmid DNA Manufacturing Distributors and Customers
  11.3. Viral Vector and Plasmid DNA Manufacturing Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)